Drings P, Manke H G
Strahlentherapie. 1985 Mar;161(3):131-3.
Hitherto, the objective of chemotherapy in case of the non-small cell bronchial carcinoma is only of a palliative nature. Thus a critical indication is necessary. This is confirmed by our investigations with the combinations of cis-platinum and ifosfamide (80 patients, remission rate 35%, median survival time of patients with remission 11,5 months), cis-platinum and vindesine (29 patients, remission rate 28%, median survival time of patients with remission 14,5 months), and ifosfamide and vepeside (63 patients, remission rate 27%, median survival time of patients with remission 12 months). The combination ifosfamide-vepeside was much better tolerated by the patients and, with its comparable remission rates and survival times, was superior to the cis-platine combinations. For the chemotherapy of the non-small cell bronchial carcinoma it has to be considered that the treatment result may be more influenced by tumor stage and activity index of the patient than by the therapy method.
迄今为止，非小细胞支气管癌的化疗目标仅具有姑息性质。因此，严格的适应症是必要的。我们对顺铂与异环磷酰胺联合用药（80例患者，缓解率35%，缓解患者的中位生存时间为11.5个月）、顺铂与长春地辛联合用药（29例患者，缓解率28%，缓解患者的中位生存时间为14.5个月）以及异环磷酰胺与依托泊苷联合用药（63例患者，缓解率27%，缓解患者的中位生存时间为12个月）的研究证实了这一点。异环磷酰胺与依托泊苷联合用药患者的耐受性要好得多，并且其缓解率和生存时间相当，优于顺铂联合用药。对于非小细胞支气管癌的化疗，必须考虑到治疗结果可能更多地受患者的肿瘤分期和活动指数影响，而非治疗方法。
